Insider Selling: Exelixis, Inc. (EXEL) Director Sells 5,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 1,318,031 shares of the company’s stock, valued at $32,950,775. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of NASDAQ EXEL traded down $0.23 during trading hours on Friday, hitting $24.53. The company had a trading volume of 4,141,757 shares, compared to its average volume of 4,072,850. The company has a market cap of $7.45 billion, a PE ratio of 17.15, a PEG ratio of 0.77 and a beta of 2.22. The company has a current ratio of 8.50, a quick ratio of 8.41 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $25.19.

Get Exelixis alerts:

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The company had revenue of $228.60 million during the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The firm’s revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.12 EPS. As a group, sell-side analysts predict that Exelixis, Inc. will post 1.04 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JOYN Advisors Inc. boosted its holdings in shares of Exelixis by 334.2% in the 4th quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,173 shares during the last quarter. FTB Advisors Inc. lifted its holdings in Exelixis by 312.0% during the 4th quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,170 shares during the last quarter. Cornerstone Advisors Inc. acquired a new stake in Exelixis during the 4th quarter valued at $38,000. Financial Gravity Companies Inc. acquired a new stake in Exelixis during the 4th quarter valued at $50,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Exelixis during the 4th quarter valued at $59,000. 75.68% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on EXEL shares. Oppenheimer set a $40.00 price target on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 15th. ValuEngine raised shares of Exelixis from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 1st. BidaskClub raised shares of Exelixis from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Finally, Zacks Investment Research cut shares of Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, February 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $29.20.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Exelixis, Inc. (EXEL) Director Sells 5,000 Shares of Stock” was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/4224649/insider-selling-exelixis-inc-exel-director-sells-5000-shares-of-stock.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: Why is the price-sales ratio important?